MILLIPORE SAS
Desconocido
VISION: From Insightful Science to Innovative Health: Strengthening Translational Capacity and Talent Intero...
Following the COVID-19 pandemic, biologicals and vaccines became regarded as salient pillars for disease prevention and control. However, st...
2023-07-04 - 2027-08-31 | Financiado
2023-07-04 - 2027-08-31 | Financiado
XVR011 Phase 2: ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS...
MILLIPORE SAS
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-CORONA-01
XVR011, ExeVir's clinical lead candidate has emerged from scientific research from labs of highly regarded virologist Xavier Saelens and bio...
2021-11-15 - 2022-11-30 | Financiado
2021-11-15 - 2022-11-30 | Financiado
nextBioPharmDSP: Next generation biopharmaceutical downstream process
MILLIPORE SAS
participó en un
H2020:
H2020-BIOTEC-2014-2015
The scope of the project is the optimization of downstream process (DSP) for the production of Biopharmaceuticals. Biopharmaceuticals have b...
2015-02-11 - 2019-02-28 | Financiado
2015-02-11 - 2019-02-28 | Financiado
* No se disponen de datos de la empresa actual.